HK Stock Movement | BRAINAURORA-B (06681) Rises Over 5% Again as Subsidiary Joins National Key R&D Program for Cognitive Disorder Treatment

Stock News2025-12-24

BRAINAURORA-B (06681) surged over 5% again, trading at HK$6.51 by press time, up 3.33%, with a turnover of HK$48.33 million.

The company announced that its wholly-owned subsidiary, Zhijingling Technology, has joined a national key R&D program—"Research on Prevention and Treatment of Cancer, Cardiovascular, Respiratory, and Metabolic Diseases"—as a key collaborator. The project, titled "Establishment and Scenario-Based Application of Key Digital Diagnosis and Treatment Technologies for Intracranial Atherosclerotic Stenosis (ICAS)-Related Cognitive Disorders Based on Deep Reasoning Large Models," has recently commenced.

Additionally, Zhijingling Technology, in collaboration with Xuanwu Hospital of Capital Medical University, has received approval to establish the "Beijing Key Laboratory of Digital Healthcare for Cognitive Disorders."

The national program focuses on addressing diagnostic and therapeutic challenges for cognitive disorders caused by ICAS. It aims to develop deep reasoning large models and a closed-loop management system for early disease screening, risk prediction, and intervention tools. As a core technology provider, BRAINAURORA-B will lead the development of deep reasoning models and digital diagnosis platforms for ICAS-related cognitive disorders.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1119716050?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-24 10:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1119716050","market":"sh","top_or_hot":-1,"title":"HK Stock Movement | BRAINAURORA-B (06681) Rises Over 5% Again as Subsidiary Joins National Key R&D Program for Cognitive Disorder Treatment","media":"Stock News","content":"<p>BRAINAURORA-B (06681) surged over 5% again, trading at HK$6.51 by press time, up 3.33%, with a turnover of HK$48.33 million.</p>\n<p>The company announced that its wholly-owned subsidiary, Zhijingling Technology, has joined a national key R&D program—\"Research on Prevention and Treatment of Cancer, Cardiovascular, Respiratory, and Metabolic Diseases\"—as a key collaborator. The project, titled \"Establishment and Scenario-Based Application of Key Digital Diagnosis and Treatment Technologies for Intracranial Atherosclerotic Stenosis (ICAS)-Related Cognitive Disorders Based on Deep Reasoning Large Models,\" has recently commenced.</p>\n<p>Additionally, Zhijingling Technology, in collaboration with Xuanwu Hospital of Capital Medical University, has received approval to establish the \"Beijing Key Laboratory of Digital Healthcare for Cognitive Disorders.\"</p>\n<p>The national program focuses on addressing diagnostic and therapeutic challenges for cognitive disorders caused by ICAS. It aims to develop deep reasoning large models and a closed-loop management system for early disease screening, risk prediction, and intervention tools. As a core technology provider, BRAINAURORA-B will lead the development of deep reasoning models and digital diagnosis platforms for ICAS-related cognitive disorders.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK Stock Movement | BRAINAURORA-B (06681) Rises Over 5% Again as Subsidiary Joins National Key R&D Program for Cognitive Disorder Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK Stock Movement | BRAINAURORA-B (06681) Rises Over 5% Again as Subsidiary Joins National Key R&D Program for Cognitive Disorder Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-24 10:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BRAINAURORA-B (06681) surged over 5% again, trading at HK$6.51 by press time, up 3.33%, with a turnover of HK$48.33 million.</p>\n<p>The company announced that its wholly-owned subsidiary, Zhijingling Technology, has joined a national key R&D program—\"Research on Prevention and Treatment of Cancer, Cardiovascular, Respiratory, and Metabolic Diseases\"—as a key collaborator. The project, titled \"Establishment and Scenario-Based Application of Key Digital Diagnosis and Treatment Technologies for Intracranial Atherosclerotic Stenosis (ICAS)-Related Cognitive Disorders Based on Deep Reasoning Large Models,\" has recently commenced.</p>\n<p>Additionally, Zhijingling Technology, in collaboration with Xuanwu Hospital of Capital Medical University, has received approval to establish the \"Beijing Key Laboratory of Digital Healthcare for Cognitive Disorders.\"</p>\n<p>The national program focuses on addressing diagnostic and therapeutic challenges for cognitive disorders caused by ICAS. It aims to develop deep reasoning large models and a closed-loop management system for early disease screening, risk prediction, and intervention tools. As a core technology provider, BRAINAURORA-B will lead the development of deep reasoning models and digital diagnosis platforms for ICAS-related cognitive disorders.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06681","symbol_name":"脑动极光-B","start_time":0,"source_url":"","article_id":"1119716050","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1119716050","pubTimestamp":1766543776,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"BRAINAURORA-B (06681) surged over 5% again, trading at HK$6.51 by press time, up 3.33%, with a turnover of HK$48.33 million. The company announced that its wholly-owned subsidiary, Zhijingling...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06681":"脑动极光-B","BK4587":"ChatGPT概念","BK4023":"应用软件","JG":"极光","BK1189":"医疗保健技术"},"translate_title":"港股动向|BRAINAURORA-B(06681)再涨超5%子公司加入国家认知障碍治疗重点研发计划","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JG":1,"06681":1},"content_text":"BRAINAURORA-B (06681) surged over 5% again, trading at HK$6.51 by press time, up 3.33%, with a turnover of HK$48.33 million.\nThe company announced that its wholly-owned subsidiary, Zhijingling Technology, has joined a national key R&D program—\"Research on Prevention and Treatment of Cancer, Cardiovascular, Respiratory, and Metabolic Diseases\"—as a key collaborator. The project, titled \"Establishment and Scenario-Based Application of Key Digital Diagnosis and Treatment Technologies for Intracranial Atherosclerotic Stenosis (ICAS)-Related Cognitive Disorders Based on Deep Reasoning Large Models,\" has recently commenced.\nAdditionally, Zhijingling Technology, in collaboration with Xuanwu Hospital of Capital Medical University, has received approval to establish the \"Beijing Key Laboratory of Digital Healthcare for Cognitive Disorders.\"\nThe national program focuses on addressing diagnostic and therapeutic challenges for cognitive disorders caused by ICAS. It aims to develop deep reasoning large models and a closed-loop management system for early disease screening, risk prediction, and intervention tools. As a core technology provider, BRAINAURORA-B will lead the development of deep reasoning models and digital diagnosis platforms for ICAS-related cognitive disorders.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1119716050","isCrawlerRequest":true}